• Researcher Profile

    Paul J. Catalano, ScD

     
    Paul J. Catalano, ScD
     
    Senior Lecturer in Biostatistics, Harvard School of Public Health

    Office phone: 617-632-2441
    Fax: 617-632-2444
    Email: pcata@jimmy.harvard.edu

    Preferred contact method: office phone
     
     

    Research Department

    Biostatistics and Computational Biology

    Area of Research

    Biostatistical Methods for Multiple Outcomes and Clustered Data


    Dana-Farber Cancer Institute
    450 Brookline Avenue
    CLSB 11007
    Boston, MA 02215

    Biography

    Dr. Catalano received his ScD in biostatistics from Harvard School of Public Health in 1991. He then completed a two-year postdoctoral fellowship there and at DFCI, joined the faculty in 1993, and became Associate Chair of the department in 2001 and Senior Lecturer in 2005. In 2007 he became Director of the Biostatistics Core Facility of the DF/HCC. His collaborative work is primarily in radiation oncology, radiology, outcomes research and cancer biology with investigators at the DF/HCC, cancer clinical trials and translational studies in gastrointestinal malignancies with the Eastern Cooperative Oncology Group and quality-of-care research in lung and colorectal cancer with the CanCORS Consortium. His methodological research is in the areas of multiple outcomes modeling and methods for hierarchical clustered data.

    Research

    Biostatistical Methods for Multiple Outcomes and Clustered Data

    The main line of my methodologic statistical research is the design and analysis of studies involving mixtures of discrete and continuous outcomes, with a focus on dose-response modeling and quantitative risk assessment. Toxicologic and other early evaluation studies in animals are a specific application area, but problems related to multiple outcomes arise in a variety of research contexts.

    One important application of such methods is the determination of overall risk from an exposure to an agent (pharmaceutical, environmental contaminant, etc.) when the outcomes are naturally multivariate. Although assessing probabilistic risk is usually straightforward with a single outcome, in the multivariate setting the situation is often more complex because outcomes may be observed simultaneously or in a hierarchical fashion. The statistical analysis must carefully account for these features of the response profile.

    My collaborative research in cancer involves statistical support for the design, monitoring, and analysis of clinical trials in gastrointestinal malignancies, design and analysis of prospective and retrospective studies in radiation oncology, radiology, outcomes research and cancer biology, collaboration on studies with quality-of-life and translational-science endpoints, and analysis of all phases of clinical trials and quality of care studies in lung cancer and colorectal cancer.

    Select Publications

    • Shyn PB, Tatli S, Sainani NI, Morrison PR, Habbab F, Catalano P, Silverman SG.  Minimizing image misregistration during PET/CT-guided percutaneous interventions using monitored breath-hold PET and CT acquisitions.  J Vasc Interv Radiol 2011; 22(9):1287-92.
    • Nikolov MC, Coull BA, Catalano PJ, Godleski JJ. Multiplicative factor analysis with a latent mixed model structure for air pollution exposure assessment.  Environmetrics  2011; 22(2):165-78.
    • Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Salz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A; Adjuvant Colon Cancer End-points (ACCENT) Group.  Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAID, X-ACT, PETACC-3, C-06, C-07 and C89803.  Eur J Cancer 2011; 47(7):990-6.  PMCID:PMC3073413
    • Margalit D, Chen YH, Catalano PJ, Heckman K, Vivenzio T, Nissen K, Wolfsberger LD, Cormack RA, Mauch P, Ng AK.  Technological advancements and error rates in radiation therapy delivery.  Int J Radiat Oncol Biology Phys 2011; 81(4): e673-9.
    • Liu R, Wolinsky JB, Catalano PJ, Chirieac LR, Wagner AJ, Grinstaff MW, Colson YL, Raut CP.  Paclitaxel-eluting polymer film reduces locoregional recurrence and improves survival in a recurrent sarcoma model:  A novel investigational therapy.  Ann Surg Oncol 2012; 19(1):199-206. 
    • Zafar SY, Malin JL, Grambow SC, Abbott DH, Kolimaga JT, Zullig LL, Weeks JC, Ayanian JZ, Kahn KL, Ganz PA, Catalano PJ, West DW, Provenzale D; for the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium. Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. Cancer 2012; Sept 12 epub.
    • Shyn PB, Oliva MR, Shah SH, Tatli S, Catalano PJ, Silverman SG.  MRI contrast enhancement of malignant liver tumours following successful cryoablation.  Eur Radiol 2012; 22(2):398-403.
    • Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fossa SD, Beard CJ.  Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2012, 84(2)Feb 18 epub.
    • Catalano PJ, Ayanian JZ, Harrington DP, Kahn KL, Landrum MB, Zaslavsky AM, Lee J, Pendergast J, Weeks J. Representativeness of participants in the Cancer Care Outcomes Research and Surveillance (CanCORS) study relative to the Surveillance, Epidemiology and End Results (SEER) Program. Medical Care, Applied Methodology Series 2012; Mar 7 epub.
    • Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, LaCasce A, Mauch PM, Ng AK. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Physics 2012; May 18 epub.
    • Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE. Microinvasive Breast Cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.  Ann Surg Oncol 2012; Sept 7 epub.
    • Shinagare AB, Shyn PB, Sadow CA, Wasser EJ, Catalano P. Incidence, appropriateness and consequences of recommendations for additional imaging tests in oncologic PET/CT reports. J Clin Radiology 2012; in press.
    • Leung CW, Ding EL, Catalano PJ, Villamor E, Rimm EB, Willett WC. Dietary intake and dietary quality of low-income adults in the supplemental nutrition assistance program. Am J Clin Nutrition 2012; 96(5):977-88. PMCID:PMC3471209.
    • Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O’Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, harper SJ. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012; Oct 25 epub.
    • Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367(17):1616-25.
    • Gilmore D, Schulz M, Liu R, Zubris KA, Padera RF, Catalano PJ, Grinstaff MW, Colson YL. Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nonoparticles delay tumor recurrence in ovarian carcinoma. Ann Surg Oncol 2012; Nov 6 epub.
    • Chakravarthy AB, Catalano PJ, Mondschein JK, Rosenthal DI, Haller DG, Whittington R, Spitz FR, Wagner H, Sigurdson ER, Tschetter LK, Bayer GK, Mulcahy MF, Benson AB. Phase II trial of paclitaxel/cisplatin followed by surgery and adjuvant radiation therapy and 5-fluorouracil/leucovorin for gastric cancer (ECOG E7296). Gastrointest Cancer Res 2012; 5(6):191-7.
    • Najita JS, Catalano PJ. On determining the BMD with multiple outcomes and intentionally missing data. Risk Analysis 2012; Dec 12 epub.
    • Chapman JW, O’Callaghan CJ,Hu N, Ding K, Yothers A, Catalano PJ, Shi W, Gray RG, O’Connell MJ, Sargent DJ. Innovative estimation of survival using log-normal survival modeling on ACCENT database. Br J Cancer 2013; Feb 5 epub.